Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Vivos Therapeutics Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
VVOS
Nasdaq
3841
https://vivos.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Vivos Therapeutics Inc
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
- Apr 9th, 2024 6:45 pm
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
- Apr 9th, 2024 11:30 am
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 4:53 pm
Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations
- Mar 31st, 2024 12:30 pm
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
- Mar 28th, 2024 8:05 pm
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
- Mar 28th, 2024 11:30 am
3 Stocks to Turn $1,000 Into $1 Million: February 2024
- Feb 22nd, 2024 5:39 pm
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
- Feb 15th, 2024 1:00 pm
Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions
- Feb 12th, 2024 2:24 pm
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
- Feb 6th, 2024 12:30 pm
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA
- Jan 8th, 2024 12:30 pm
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”
- Dec 11th, 2023 12:30 pm
Vivos receives FDA 510(k) clearance for oral devices to treat severe sleep apnea
- Nov 30th, 2023 6:20 am
Vivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apnea
- Nov 29th, 2023 6:04 pm
UPDATE 2-US FDA clears Vivos Therapeutics' oral device for sleep apnea
- Nov 29th, 2023 1:07 pm
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
- Nov 29th, 2023 12:30 pm
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
- Nov 14th, 2023 9:05 pm
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
- Nov 9th, 2023 9:30 pm
Vivos Therapeutics agrees to nationwide distribution deal with in-home respiratory dealer Lincare
- Nov 3rd, 2023 5:51 pm
Vivos Therapeutics Closes $4 Million Private Placement
- Nov 2nd, 2023 9:00 pm
Scroll